Abstract:This study describes the effect of ethanol and the presence of poly(ethylene) glycol (PEG) lipids on the interaction of nucleotide-based polyelectrolytes with cationic liposomes. It is shown that preformed large unilamellar vesicles (LUVs) containing a cationic lipid and a PEG coating can be induced to entrap polynucleotides such as antisense oligonucleotides and plasmid DNA in the presence of ethanol. The interaction of the cationic liposomes with the polynucleotides leads to the formation of multilamellar li… Show more
“…The resulting cationic liposomes were 60 nm in diameter and exhibited a zeta potential of ~40 mV. As previously reported, 15,25 size was found to increase slightly on complexation with siRNA molecules and zeta potentials also decreased accordingly. Particle size showed a maximum at N/P ratio of 5.…”
Section: Preparation and Characterization Of Lipoplexes And Lnpssupporting
confidence: 81%
“…15,25 Cationic liposomes were composed of the following lipids: DODMA, PEG-DSPE, DSPC and cholesterol in a molar ratio of 50:1.5:10:38.5. Lipids were dissolved in 3 mL ethanol and then 70.5 µL 1N HCl and 6.93 mL distilled water were added to this mixture (total lipids: 7.8 mg/mL).…”
Two lipid-based nanoformulations have been used to date in clinical studies: lipoplexes and lipid nanoparticles (LNPs). In this study, we prepared small interfering RNA (siRNA)-loaded carriers using lipid components of the same composition to form molecular assemblies of differing structures, and evaluated the impact of structure on cellular uptake and immune stimulation. Lipoplexes are electrostatic complexes formed by mixing preformed cationic lipid liposomes with anionic siRNA in an aqueous environment, whereas LNPs are nanoparticles embedding siRNA prepared by mixing an alcoholic lipid solution with an aqueous siRNA solution in one step. Although the physicochemical properties of lipoplexes and LNPs were similar except for small increases in apparent size of lipoplexes and zeta potential of LNPs, siRNA uptake efficiency of LNPs was significantly higher than that of lipoplexes. Furthermore, in the case of LNPs, both siRNA and lipid were effectively incorporated into cells in a co-assembled state; however, in the case of lipoplexes, the amount of siRNA internalized into cells was small in comparison with lipid. siRNAs in lipoplexes were thought to be more likely to localize on the particle surface and thereby undergo dissociation into the medium. Inflammatory cytokine responses also appeared to differ between lipoplexes and LNPs. For tumor necrosis factor-α, release was mainly caused by siRNA. On the other hand, the release of interleukin-1β was mainly due to the cationic nature of particles. LNPs released lower amounts of tumor necrosis factor-α and interleukin-1β than lipoplexes and were thus considered to be better tolerated with respect to cytokine release. In conclusion, siRNA-loaded nanoformulations effect their cellular uptake and immune stimulation in a manner that depends on the structure of the molecular assembly; therefore, nanoformulations should be optimized before extending studies into the in vivo environment.
“…The resulting cationic liposomes were 60 nm in diameter and exhibited a zeta potential of ~40 mV. As previously reported, 15,25 size was found to increase slightly on complexation with siRNA molecules and zeta potentials also decreased accordingly. Particle size showed a maximum at N/P ratio of 5.…”
Section: Preparation and Characterization Of Lipoplexes And Lnpssupporting
confidence: 81%
“…15,25 Cationic liposomes were composed of the following lipids: DODMA, PEG-DSPE, DSPC and cholesterol in a molar ratio of 50:1.5:10:38.5. Lipids were dissolved in 3 mL ethanol and then 70.5 µL 1N HCl and 6.93 mL distilled water were added to this mixture (total lipids: 7.8 mg/mL).…”
Two lipid-based nanoformulations have been used to date in clinical studies: lipoplexes and lipid nanoparticles (LNPs). In this study, we prepared small interfering RNA (siRNA)-loaded carriers using lipid components of the same composition to form molecular assemblies of differing structures, and evaluated the impact of structure on cellular uptake and immune stimulation. Lipoplexes are electrostatic complexes formed by mixing preformed cationic lipid liposomes with anionic siRNA in an aqueous environment, whereas LNPs are nanoparticles embedding siRNA prepared by mixing an alcoholic lipid solution with an aqueous siRNA solution in one step. Although the physicochemical properties of lipoplexes and LNPs were similar except for small increases in apparent size of lipoplexes and zeta potential of LNPs, siRNA uptake efficiency of LNPs was significantly higher than that of lipoplexes. Furthermore, in the case of LNPs, both siRNA and lipid were effectively incorporated into cells in a co-assembled state; however, in the case of lipoplexes, the amount of siRNA internalized into cells was small in comparison with lipid. siRNAs in lipoplexes were thought to be more likely to localize on the particle surface and thereby undergo dissociation into the medium. Inflammatory cytokine responses also appeared to differ between lipoplexes and LNPs. For tumor necrosis factor-α, release was mainly caused by siRNA. On the other hand, the release of interleukin-1β was mainly due to the cationic nature of particles. LNPs released lower amounts of tumor necrosis factor-α and interleukin-1β than lipoplexes and were thus considered to be better tolerated with respect to cytokine release. In conclusion, siRNA-loaded nanoformulations effect their cellular uptake and immune stimulation in a manner that depends on the structure of the molecular assembly; therefore, nanoformulations should be optimized before extending studies into the in vivo environment.
“…MLP/siRNA complexes were made as previously reported. 10,35,37 As shown in Figure 2A, we found that MLP had strong ability to bind siRNA, which completely complexed siRNA at an N/P ratio of 5:1 (the molar ratio of nitrogen in MLP to phosphate in siRNA) through electrostatic interaction, leading to no free siRNA in the gel. The control liposome (DLP) was prepared by PD, DSPE-PEG2000, and cholesterol, and was mixed with siRNA in pH=3 citrate buffer at the optimal N/P ratio of 5:1 ( Figure S2).…”
Section: Results and Discussion Synthesis And Physiochemical Propertimentioning
Here, we report the hypoxia-responsive ionizable liposomes to deliver small interference RNA (siRNA) anticancer drugs, which can selectively enhance cellular uptake of the siRNA under hypoxic and low-pH conditions to cure glioma. For this purpose, malate dehydrogenase lipid molecules were synthesized, which contain nitroimidazole groups that impart hypoxia sensitivity and specificity as hydrophobic tails, and tertiary amines as hydrophilic head groups. These malate dehydrogenase molecules, together with DSPE-PEG2000 and cholesterol, were self-assembled into O′
1
,O
1
-(3-(dimethylamino)propane-1,2-diyl) 16-bis(2-(2-methyl-5-nitro-1
H
-imidazol-1-yl)ethyl) di(hexadecanedioate) liposomes (MLP) to encapsulate siRNA through electrostatic interaction. Our study showed that the MLP could deliver polo-like kinase 1 siRNA (siPLK1) into glioma cells and effectively enhance the cellular uptake of MLP/siPLK1 because of increased positive charges induced by hypoxia and low pH. Moreover, MLP/siPLK1 was shown to be very effective in inhibiting the growth of glioma cells both in vitro and in vivo. Therefore, the MLP is a promising siRNA delivery system for tumor therapy.
“…Construction of siRNA-encapsulated Liposomes-siRNAencapsulated liposomes, called stable nucleic acid lipid particles (SNALPs), were prepared according to a method reported previously (25). 1,2-dioleyloxy-3-(dimethylamino)propane, 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine, cholesterol (2,15-dimethyl-14-(1,5-dimethylhexyl)tetracyclo-heptadec-7-en-5-ol), and PEG2000PE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL) and dissolved in ethanol at a molar ratio of 40:10:47:3.…”
The siRNA silencing approach has long been used as a method to regulate the expression of specific target genes in vitro and in vivo. However, the effectiveness of delivery and the nonspecific immune-stimulatory function of siRNA are the limiting factors for therapeutic applications of siRNAs. To overcome these limitations, we developed self-assembled micelle inhibitory RNA (SAMiRNA) nanoparticles made of individually biconjugated siRNAs with a hydrophilic polymer and lipid on their ends and characterized their stability, immune-stimulatory function, and in vivo silencing efficacy. SAMiRNAs form very stable nanoparticles with no significant degradation in size distribution and polydispersity index over 1 year. Overnight incubation of SAMiRNAs (3 M) on murine peripheral blood mononuclear cells did not cause any significant elaboration of innate immune cytokines such as TNF-␣, IL-12, or IL-6, whereas unmodified siRNAs or liposomes or liposome complexes significantly stimulated the expression of these cytokines. Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting amphiregulin and connective tissue growth factor in bleomycin or TGF- transgenic animal models of pulmonary fibrosis. Intratracheal or intravenous delivery two or three times of amphiregulin or connective tissue growth factor SAMiRNAs significantly reduced the bleomycin-or TGF--stimulated collagen accumulation in the lung and substantially restored the lung function of TGF- transgenic mice. This study demonstrates that SAMiRNA nanoparticle is a less toxic, stable siRNA silencing platform for efficient in vivo targeting of genes implicated in the pathogenesis of pulmonary fibrosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.